What Oddifact does

Oddifact is a privately held French biotech technology company headquartered in Paris that operates an artificial intelligence platform for drug repositioning in rare diseases. The platform identifies orphan drug applications for existing medicines, validates candidates, and accelerates regulatory pathways to convert off-label use into approved orphan drug designations. The company claims 73% workflow automation through AI and the ability to move from candidate selection to FDA submission in 10 days, with an operational track record of 11 granted Orphan Drug Designations across the US and Europe, 16 FDA submissions, and a #1 global ranking for FDA Orphan Drug Designations in 2024. Its pipeline is organized around repositioning established molecules such as infliximab (for IVIG-resistant Kawasaki disease) and the MabionCD20 antibody (under a 2026 letter of intent with Mabion S.A.), with a stated ambition of 30-50 new rare disease treatments by 2030.

The business model is B2B, targeting pharmaceutical and biotech companies through direct enterprise partnerships and strategic co-development agreements, with revenue expected to derive from licensing, royalties, and milestone payments. The company operates with 11-50 employees and is founder-led by Pierre-Alexandre Teulié, with no disclosed external institutional investors, funding rounds, or revenue figures. Distribution is conducted through direct field sales and high-profile industry engagement (e.g., Digital Health & AI Innovation Summit in Boston), supplemented by an active newsroom and a B2B website positioning.

Oddifact's primary customer segments are pharmaceutical and biotech companies seeking to expand into rare disease indications and the 300 million+ global rare disease patient population, 95% of whom have no approved treatment. While the company's regulatory throughput is exceptional for its size, the absence of disclosed revenue, funding, or commercialized products means financial maturity lags its regulatory and reputational maturity.

Name

Oddifact

Legal name

Oddifact

Website

https://oddifact.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Oddifact is a Paris-based AI biotech platform that uses artificial intelligence to reposition existing drugs into approved orphan drug treatments for rare diseases, serving pharmaceutical and biotech companies. It holds 14 US/EU Orphan Drug Designations and ranks #1 globally for FDA ODDs in 2024.

Ownership category

akta.pro rank

Product category

AI-driven orphan drug repositioning platform

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

akta.pro secondary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

Keywords

• Drug repositioning platform
• Orphan drug development
• Rare disease therapeutics
• AI drug discovery
• Orphan drug designation

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Orphan Drug Development Services: AI-powered platform services for pharmaceutical companies seeking to reposition existing drugs for rare disease applications. Revenue likely derived from licensing technology, strategic partnerships, and milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Oddifact operates an AI-driven platform that identifies, validates, and accelerates regulatory pathways for repurposing existing drugs as therapies for rare diseases. The company helps pharmaceutical and biotechnology firms shorten the development timeline for orphan drug indications by combining artificial intelligence with regulatory expertise.

Product overview

Oddifact operates as a single unified AI-driven platform for drug repositioning in rare diseases. The core offering is an AI platform that identifies orphan drug applications for existing medicines, validates these opportunities, and accelerates regulatory pathways to turn off-label use into approved orphan drugs. The platform is supported by strategic collaborations with biotech partners like Mabion S.A. for specific drug programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Oddifact AI Orphan Drug Repositioning Platform

Quantifiable outcome

• 73% workflow automation with AI
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Mabion S.A.coreStrategic or Co-development Partner · 17 June 2026Polish biotech Mabion signed a letter of intent with Oddifact to explore MabionCD20 as a treatment for rare diseases, reopening a program previously developed as a rituximab biosimilar. The agreement leverages Mabion's antibody development and manufacturing expertise alongside Oddifact's AI platform designed to identify orphan drug applications for existing medicines. This partnership marks a strategic pivot for the CD20 asset, potentially opening a new market pathway through the rare disease space.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Biovista: Drug repositioning company using AI to identify new indications for existing drugs. Directly comparable to Oddifact's repositioning methodology, particularly for rare and orphan diseases.
• Atomwise: AI-driven small molecule discovery company using structure-based design. Comparable in applying AI to accelerate early-stage drug development, though focused on novel chemistry.

Regional players

• Owkin: French AI-biotech company applying machine learning to biomedical research and drug development. Comparable as a French AI-healthcare peer, though more focused on data analysis than repositioning.
• Iktos: Paris-based AI company specializing in generative chemistry and small molecule design. Comparable to Oddifact as a French AI-biotech peer, though focused on de novo design rather than repositioning.

Direct peers

• Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology to develop therapeutics. Comparable to Oddifact's AI-first approach to drug development.
• Pharnext: French biotech focused on drug repositioning (pleotherapy) for rare neurological diseases. Comparable to Oddifact in both the repositioning methodology and French/European origin.
• Exscientia: AI-native pharmatech company using AI to design and develop new drug candidates. Comparable in applying AI to compress drug discovery timelines, though focused more on novel chemistry than repositioning.
• BenevolentAI: AI-driven drug discovery company with a focus on identifying new uses for existing molecules and rare disease indications. Directly comparable to Oddifact's repositioning approach and AI-native platform strategy.
• Recursion Pharmaceuticals: AI-enabled drug discovery platform combining high-throughput biology with machine learning. Comparable to Oddifact in using AI to accelerate drug identification and pipeline development across multiple therapeutic areas.
• Healx: AI-driven rare disease drug discovery company focused on drug repurposing. Closely aligned with Oddifact's positioning at the intersection of AI, drug repositioning, and rare disease therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oddifact
• Xx.com/oddifact8093

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oddifact